Cellectis (CLLS) EBIT Growth (1y) (2016 - 2026)
Powered by 
Analysis
Cellectis (CLLS) EBIT Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -36.55% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 99.51% |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -145.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -145.37% |
| Mar 31, 2026 | -77.49% |
| Dec 31, 2025 | -243.25% |
| Sep 30, 2025 | 174.67% |
| Jun 30, 2025 | 44.30% |
| Mar 31, 2025 | 32.14% |
| Dec 31, 2024 | 128.98% |
| Sep 30, 2024 | 47.90% |
| Jun 30, 2024 | 27.14% |
| Mar 31, 2024 | 24.93% |
| Dec 31, 2023 | -638.43% |
| Sep 30, 2023 | 24.43% |
| Jun 30, 2023 | 13.52% |
| Mar 31, 2023 | 4.77% |
| Dec 31, 2022 | 76.95% |
| Sep 30, 2022 | 35.44% |
| Jun 30, 2022 | 27.13% |
| Mar 31, 2022 | -46.82% |
| Dec 31, 2021 | -162.71% |
| Sep 30, 2021 | -44.34% |